LATESTSEARCH ⌕
NASDAQ / LIVE COMPANY INTELLIGENCE

Jazz Pharmaceuticals plc

Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.

TICKERJAZZ
CORENasdaq-listed company
WATCHEarnings + filings + operating news
STATUSContinuously updated
LIVE / JAZZ COVERAGE

What’s moving Jazz Pharmaceuticals plc now

Current reporting with the operating signal separated from the noise.

01
Jazz Pharmaceuticals plc publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026

Jazz Pharmaceuticals plc publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026

The story matters when it changes Jazz Pharmaceuticals plc’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
02
Transcript : Jazz Pharmaceuticals plc, Q2 2026 Earnings Call, Aug 03, 2026

Transcript : Jazz Pharmaceuticals plc, Q2 2026 Earnings Call, Aug 03, 2026

Investors are testing whether Jazz Pharmaceuticals plc’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
03
Jazz Pharmaceuticals PLC (JAZZ): CBD-Based Epidiolex Drug Sales Up 15%

Jazz Pharmaceuticals PLC (JAZZ): CBD-Based Epidiolex Drug Sales Up 15%

The story matters when it changes Jazz Pharmaceuticals plc’s customers, execution, competitive position or capital requirements.

Watch next: official volume, pricing, inventory and segment margin.
04
Jazz Pharmaceuticals plc (JAZZ) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Jazz Pharmaceuticals plc (JAZZ) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

The story matters when it changes Jazz Pharmaceuticals plc’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
05
Jazz Pharmaceuticals plc (JAZZ) Advances Rare Cancer Portfolio with First CNS Glioma Therapy Approval

Jazz Pharmaceuticals plc (JAZZ) Advances Rare Cancer Portfolio with First CNS Glioma Therapy Approval

The story matters when it changes Jazz Pharmaceuticals plc’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
06
Jazz Pharmaceuticals plc (JAZZ) Q2 2025 Earnings Call Transcript

Jazz Pharmaceuticals plc (JAZZ) Q2 2025 Earnings Call Transcript

Investors are testing whether Jazz Pharmaceuticals plc’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
07
What Makes Jazz Pharmaceuticals plc (JAZZ) a Prospective Investment Bet?

What Makes Jazz Pharmaceuticals plc (JAZZ) a Prospective Investment Bet?

The story matters when it changes Jazz Pharmaceuticals plc’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
PRIMARY DOCUMENTS / SEC EDGAR

Latest JAZZ filings.

Investor-relevant reports are shown first, followed by the company’s other recent official submissions.

10-QQuarterly financial reportFiled 2026-08-03 · Period 2026-06-30SEC ↗10-QQuarterly financial reportFiled 2026-05-05 · Period 2026-03-31SEC ↗10-K/AAnnual financial reportFiled 2026-04-24 · Period 2025-12-31SEC ↗8-KMaterial company eventFiled 2026-08-03 · Period 2026-08-03SEC ↗8-KMaterial company eventFiled 2026-07-24 · Period 2026-07-23SEC ↗8-KMaterial company eventFiled 2026-05-29 · Period 2026-05-25SEC ↗DEF 14AProxy and shareholder meetingFiled 2026-06-08 · Period 2026-07-23SEC ↗144Official SEC filingFiled 2026-08-03SEC ↗
EARNINGS / QUARTERLY TRACKER

Jazz Pharmaceuticals plc, quarter by quarter.

Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.